In this article, the roughly $1,000 monthly cost of Eli Lilly’s weight loss drug Zepbound has made it unaffordable for Willow Baillies, 29, whose insurance does not cover it. Baillies, a human resources specialist from Milwaukee, Wisconsin, has been struggling with weight loss and chronic autoimmune issues. To find a more affordable option, she turned to a compounded, off-brand version of tirzepatide, the active ingredient in Zepbound and Eli Lilly’s diabetes drug Mounjaro.
Baillies reported significant improvements in her health since starting the compounded tirzepatide, experiencing relief from autoimmune pain and losing about 52 pounds at a cost of around $350 per month. However, the FDA’s recent announcement that branded tirzepatide is no longer in short supply may limit access to compounded versions in the near future.
Patients and healthcare experts fear that this decision could lead to challenges for those who rely on compounded tirzepatide, potentially forcing them to stockpile doses, switch treatments, or face financial barriers to care. The FDA’s move aims to increase availability of Zepbound for patients with insurance coverage, reflecting Eli Lilly’s efforts to boost manufacturing for tirzepatide.
While this decision may benefit some patients, it leaves others in uncertainty, closing off a market for compounded tirzepatide that filled a gap in care for those unable to afford Zepbound. Many patients are concerned about the potential impact on their treatment and are exploring alternative options, including switching to other medications or seeking assistance through savings programs.
The ongoing legal battle between the FDA and the Outsourcing Facilities Association adds to the confusion surrounding the future availability of compounded tirzepatide. Patients like Amanda Bonello and Erin Hunt, who have seen positive results from the compounded drug, are uncertain about their treatment options moving forward. The potential discontinuation of compounded tirzepatide raises concerns for patients who rely on these medications for weight loss and other health benefits.
As patients navigate these changes, some may consider turning to alternative sources for the drug, such as underground markets or unbranded versions. However, healthcare professionals caution against these practices due to safety concerns. The evolving landscape of compounded medications underscores the challenges faced by patients seeking affordable and effective treatments for conditions like obesity and diabetes.
